Remove 2021 Remove Licensing Remove Therapies
article thumbnail

Actithera draws new investors to radiopharma drug pitch

BioPharma Drive: Drug Pricing

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. subsidiary of Merck KGaA, is the founder of radioligand therapy developer Actithera. You can unsubscribe at anytime.

Drugs 155
article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Drug development faces significant challenges: long timelines, high costs , complex processes and low probabilities of success (PoS), exacerbated by the shift towards more complex molecules, biologics and cell and gene therapies, hindering patient access to vital treatments. Nature, 596, 590-596 (2021) [link] Liu R, Rizzo S, Waliany S, et al.

Drugs 65
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Inavolisib

New Drug Approvals

3] Primary endocrine resistance was defined as relapse while on the first two years of adjuvant endocrine therapy (ET) and secondary endocrine resistance was defined as relapse while on adjuvant ET after at least two years or relapse within twelve months of completing adjuvant ET. [3] New Drug Therapy Approvals 2024 (PDF). PMC 9297732.

FDA 57
article thumbnail

Vamorolone

New Drug Approvals

Corticosteroid therapy is the current standard of care for DMD despite relatively high rates of adverse effects. 7 (2021) 13. [70] 75,76 This also results in decreased glucocorticoid receptor-drive transactivation, ultimately improving the safety profile of vamorolone as compared to other corticosteroid therapies. Goemans, S.

FDA 57
article thumbnail

Pirtobrutinib

New Drug Approvals

MORE US10918622 US10695323 US10464905 US10342780 US12109193 Medical uses In the United States, pirtobrutinib is indicated to treat relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. [1] 5] It is taken by mouth. [1] 2] PATENTS Guisot, N.

article thumbnail

Taletrectinib

New Drug Approvals

3] The US Food and Drug Administration (FDA) granted the application for taletrectinib priority review , breakthrough therapy , and orphan drug designations. [3] World Health Organization (2021). 3] Participants may have received prior chemotherapy for advanced disease. [3] 5] Taletrectinib is sold under the brand name Ibtrozi. [3]

article thumbnail

Vor, with new CEO, changes course to target autoimmune disease

BioPharma Drive: Drug Pricing

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. Vor Biopharma licensed a drug in June 2025 that targets proteins essential to B cell survival.

Disease 109